Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Nadunolimab for Current or Former Smokers With High-risk Lung Nodules.

NCT07284485 is registered in ClinicalTrials.gov with Robert Samstein as lead sponsor.

NCT NCT07284485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07284485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Nadunolimab for Current or Former Smokers With High-risk Lung Nodules.
Lead sponsor
Robert Samstein
Phase
Phase 2
Overall status
Recruiting
Start date
May 21, 2026
Completion date
December 17, 2029
Enrollment
59 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk lung nodules